Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Feb;8(1):100749.
doi: 10.1016/j.esmoop.2022.100749. Epub 2023 Jan 3.

Off-label, but on target: the evidence needed to implement alternative dosing regimens of anticancer drugs

J K Overbeek  1 , R Ter Heine  1 , H M W Verheul  2 , E Chatelut  3 , M A Rudek  4 , H Gurney  5 , R Plummer  6 , D C Gilbert  7 , T Buclin  8 , D M Burger  1 , H J Bloemendal  9 , N P van Erp  10
Affiliations
Editorial

Off-label, but on target: the evidence needed to implement alternative dosing regimens of anticancer drugs

J K Overbeek et al. ESMO Open. 2023 Feb.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Required level of evidence needed for implementation of different types of alternative dosing regimens. The y-axis represents cumulative pharmacokinetic exposure. Dotted horizontal lines represent the clinical no-effect boundaries for exposure. On the x-axis different alternative dosing regimens are represented. These are categorized into three subtypes: leading to equivalent exposure (pink), lower or shorter exposure (green), or higher exposure (gray). Top bars indicate the proposed evidence required for implementation. The dots represent the relevant pharmacokinetic exposure parameter of alternative dosing regimens, chosen at random to illustrate the examples.
See this image and copyright information in PMC

References

    1. Maliepaard M., Carree W., van Bussel MTJ Dose selection and tolerability of anticancer agents evaluated by the European Medicines Agency in the period 2015-2020. ESMO Open. 2021;6(6) - PMC - PubMed
    1. Shah M., Rahman A., Theoret M.R., Pazdur R. The drug-dosing conundrum in oncology – when less is more. N radEngl J Med. 2021;385(16):1445–1447. - PubMed
    1. World Health Organization Technical report: pricing of cancer medicines and its impacts: a comprehensive technical report for the World Health Assembly Resolution 70.12: operative paragraph 2.9 on pricing approaches and their impacts on availability and affordability of medicines for the prevention and treatment of cancer. World Health Organization. 2018. https://apps.who.int/iris/handle/10665/277190 Available at.
    1. Serritella A.V., Strohbehn G.W., Goldstein D.A., Lichter A.S., Ratain M.J. Interventional pharmacoeconomics: a novel mechanism for unlocking value. Clin Pharmacol Ther. 2020;108(3):487–493. - PubMed
    1. Lubberman F.J.E., Gelderblom H., Hamberg P., et al. The effect of using pazopanib with food vs. fasted on pharmacokinetics, patient safety, and preference (DIET Study) Clin Pharmacol Ther. 2019;106(5):1076–1082. - PubMed

Publication types

Substances